These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36889696)

  • 1. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
    Liu Y; Zhao X; Jian J; Hasan S; Liu C
    Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease.
    Zhao X; Liberti R; Jian J; Fu W; Hettinghouse A; Sun Y; Liu CJ
    J Mol Med (Berl); 2021 Nov; 99(11):1639-1654. PubMed ID: 34453183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase.
    Fog CK; Zago P; Malini E; Solanko LM; Peruzzo P; Bornaes C; Magnoni R; Mehmedbasic A; Petersen NHT; Bembi B; Aerts JFMG; Dardis A; Kirkegaard T
    EBioMedicine; 2018 Dec; 38():142-153. PubMed ID: 30497978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.
    Lin Y; Zhao X; Liou B; Fannin V; Zhang W; Setchell KDR; Wang X; Pan D; Grabowski GA; Liu CJ; Sun Y
    Hum Mol Genet; 2024 Aug; ():. PubMed ID: 39101473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions.
    Pavan E; Peruzzo P; Cattarossi S; Bergamin N; Bordugo A; Sechi A; Scarpa M; Biasizzo J; Colucci F; Dardis A
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of GM1-Ganglioside Secondary Accumulation in Fibroblasts from Neuropathic Gaucher Patients and Effect of a Trivalent Trihydroxypiperidine Iminosugar Compound on Its Storage Reduction.
    Ceni C; Clemente F; Mangiavacchi F; Matassini C; Tonin R; Caciotti A; Feo F; Coviello D; Morrone A; Cardona F; Calamai M
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38257371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease.
    Jian J; Chen Y; Liberti R; Fu W; Hu W; Saunders-Pullman R; Pastores GM; Chen Y; Sun Y; Grabowski GA; Liu CJ
    EBioMedicine; 2018 Feb; 28():251-260. PubMed ID: 29396296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.
    Cyske Z; Gaffke L; Rintz E; Wiśniewska K; Węgrzyn G; Pierzynowska K
    Neurochem Int; 2024 Sep; 178():105774. PubMed ID: 38797393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase.
    Takahashi H; Bhagwagar S; Nies SH; Ye H; Han X; Chiasseu MT; Wang G; Mackenzie IR; Strittmatter SM
    Nat Commun; 2024 Feb; 15(1):1434. PubMed ID: 38365772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease.
    Srikanth MP; Feldman RA
    Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.
    Logan T; Simon MJ; Rana A; Cherf GM; Srivastava A; Davis SS; Low RLY; Chiu CL; Fang M; Huang F; Bhalla A; Llapashtica C; Prorok R; Pizzo ME; Calvert MEK; Sun EW; Hsiao-Nakamoto J; Rajendra Y; Lexa KW; Srivastava DB; van Lengerich B; Wang J; Robles-Colmenares Y; Kim DJ; Duque J; Lenser M; Earr TK; Nguyen H; Chau R; Tsogtbaatar B; Ravi R; Skuja LL; Solanoy H; Rosen HJ; Boeve BF; Boxer AL; Heuer HW; Dennis MS; Kariolis MS; Monroe KM; Przybyla L; Sanchez PE; Meisner R; Diaz D; Henne KR; Watts RJ; Henry AG; Gunasekaran K; Astarita G; Suh JH; Lewcock JW; DeVos SL; Di Paolo G
    Cell; 2021 Sep; 184(18):4651-4668.e25. PubMed ID: 34450028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances.
    Huang G; Jian J; Liu CJ
    Cytokine Growth Factor Rev; 2024 Apr; 76():142-159. PubMed ID: 37981505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. pH-Responsive Trihydroxylated Piperidines Rescue The Glucocerebrosidase Activity in Human Fibroblasts Bearing The Neuronopathic Gaucher-Related L444P/L444P Mutations in GBA1 Gene.
    Davighi MG; Matassini C; Clemente F; Paoli P; Morrone A; Cacciarini M; Goti A; Cardona F
    Chembiochem; 2024 Jan; 25(1):e202300730. PubMed ID: 37877519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microglia regulate brain progranulin levels through the endocytosis/lysosomal pathway.
    Dong T; Tejwani L; Jung Y; Kokubu H; Luttik K; Driessen TM; Lim J
    JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34618685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR Correction of the GBA Mutation in Human-Induced Pluripotent Stem Cells Restores Normal Function to Gaucher Macrophages and Increases Their Susceptibility to Mycobacterium tuberculosis.
    Ramalingam S; Kumar A; Krug S; Mohan H; Rao DN; Bishai WR; Chandrasegaran S
    J Infect Dis; 2023 Sep; 228(6):777-782. PubMed ID: 37159513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach.
    Feng S; Rcheulishvili N; Jiang X; Zhu P; Pan X; Wei M; Wang PG; Ji Y; Papukashvili D
    Int J Biol Sci; 2024; 20(6):2111-2129. PubMed ID: 38617529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson's disease.
    Williams D; Glasstetter LM; Jong TT; Kapoor A; Zhu S; Zhu Y; Gehrlein A; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
    bioRxiv; 2024 Mar; ():. PubMed ID: 38712038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher disease protects against tuberculosis.
    Fan J; Hale VL; Lelieveld LT; Whitworth LJ; Busch-Nentwich EM; Troll M; Edelstein PH; Cox TM; Roca FJ; Aerts JMFG; Ramakrishnan L
    Proc Natl Acad Sci U S A; 2023 Feb; 120(7):e2217673120. PubMed ID: 36745788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.